Clinical course of SARS-CoV-2 infection and recovery in lung transplant recipients.
COVID-19
SARS-CoV-2
acute lung allograft dysfunction
clinical outcomes
lung transplantation
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
revised:
03
08
2022
received:
20
06
2022
accepted:
26
08
2022
pubmed:
23
10
2022
medline:
24
12
2022
entrez:
22
10
2022
Statut:
ppublish
Résumé
Reports on outcomes following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in lung transplant recipients remain limited. We performed a single-center, observational study of outcomes in lung transplant recipients diagnosed with SARS-CoV-2 between 5/1/2020 and 3/15/2022 that were followed for a median of 123 days. We analyzed changes in spirometry, acute lung allograft dysfunction (ALAD) incidence, hospitalization, mechanical ventilation needs, secondary infection, and survival. In our cohort of 336 patients, 103 developed coronavirus disease (COVID) (27 pre-Delta, 20 Delta, and 56 Omicron-era). Twenty-five patients (24%) required hospitalization and 10 patients ultimately died (10%). Among 85 survivors who completed ambulatory spirometry, COVID-19 did not alter change in forced expiratory volume in 1 s (FEV This study describes the natural history of SARS-CoV-2 infection in a large cohort of lung transplant recipients. Although one third of patients develop ALAD requiring augmented immunosuppression, infection with SARS-CoV-2 is not associated with worsening lung function.
Sections du résumé
BACKGROUND
BACKGROUND
Reports on outcomes following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in lung transplant recipients remain limited.
METHODS
METHODS
We performed a single-center, observational study of outcomes in lung transplant recipients diagnosed with SARS-CoV-2 between 5/1/2020 and 3/15/2022 that were followed for a median of 123 days. We analyzed changes in spirometry, acute lung allograft dysfunction (ALAD) incidence, hospitalization, mechanical ventilation needs, secondary infection, and survival.
RESULTS
RESULTS
In our cohort of 336 patients, 103 developed coronavirus disease (COVID) (27 pre-Delta, 20 Delta, and 56 Omicron-era). Twenty-five patients (24%) required hospitalization and 10 patients ultimately died (10%). Among 85 survivors who completed ambulatory spirometry, COVID-19 did not alter change in forced expiratory volume in 1 s (FEV
CONCLUSIONS
CONCLUSIONS
This study describes the natural history of SARS-CoV-2 infection in a large cohort of lung transplant recipients. Although one third of patients develop ALAD requiring augmented immunosuppression, infection with SARS-CoV-2 is not associated with worsening lung function.
Identifiants
pubmed: 36271645
doi: 10.1111/tid.13967
pmc: PMC9780187
mid: NIHMS1844336
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13967Subventions
Organisme : NHLBI NIH HHS
ID : K08 HL136888
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL160551
Pays : United States
Organisme : NIH HHS
ID : K08 HL136888
Pays : United States
Informations de copyright
© 2022 The Authors. Transplant Infectious Disease published by Wiley Periodicals LLC.
Références
Transplantation. 2021 Nov 1;105(11):e263-e264
pubmed: 34310530
Am J Transplant. 2019 Jan;19(1):21-31
pubmed: 29956477
Nat Rev Immunol. 2021 Jun;21(6):382-393
pubmed: 33875867
Am J Transplant. 2022 Feb;22(2):634-639
pubmed: 34551181
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1468-1470
pubmed: 32209030
Clin Microbiol Infect. 2021 Mar;27(3):451-457
pubmed: 33223114
J Heart Lung Transplant. 2021 Sep;40(9):936-947
pubmed: 34172387
Clin Transplant. 2013 Jan-Feb;27(1):E64-71
pubmed: 23278569
Am J Respir Crit Care Med. 2021 Feb 1;203(3):307-317
pubmed: 33480831
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88
pubmed: 31613151
Transplantation. 2021 Jan 1;105(1):177-186
pubmed: 33141808
PLoS One. 2021 Oct 6;16(10):e0257807
pubmed: 34613977
J Heart Lung Transplant. 2007 Dec;26(12):1229-42
pubmed: 18096473
J Heart Lung Transplant. 2016 Apr;35(4):397-406
pubmed: 27044531
Lancet Respir Med. 2021 Jun;9(6):e52-e53
pubmed: 33964244
J Heart Lung Transplant. 2020 Nov;39(11):1171-1190
pubmed: 32773322
Clin Transplant. 2022 Mar;36(3):e14540
pubmed: 34792221
Am J Transplant. 2021 May;21(5):1816-1824
pubmed: 33089648
Transfus Med. 2021 Aug;31(4):292-302
pubmed: 33955079
JAMA Netw Open. 2021 Mar 1;4(3):e210417
pubmed: 33666657
J Heart Lung Transplant. 2021 Aug;40(8):763-766
pubmed: 34144891
JAMA Intern Med. 2022 Feb 1;182(2):153-162
pubmed: 34962505
J Thorac Dis. 2014 Aug;6(8):1039-53
pubmed: 25132971
Curr Opin Organ Transplant. 2015 Oct;20(5):492-7
pubmed: 26262460
J Heart Lung Transplant. 2021 Dec;40(12):1579-1588
pubmed: 34456108
Am J Transplant. 2021 Aug;21(8):2774-2784
pubmed: 34008917
Am J Transplant. 2020 Nov;20(11):3234-3238
pubmed: 32659857
J Infect Public Health. 2022 Mar;15(3):365-372
pubmed: 35193818
Eur J Clin Invest. 2020 Oct;50(10):e13376
pubmed: 32880939
Transpl Infect Dis. 2022 Feb;24(1):e13759
pubmed: 34787345
Transplantation. 2021 Sep 1;105(9):2072-2079
pubmed: 34075005
Thorax. 2021 Dec;76(12):1242-1245
pubmed: 33927016
J Heart Lung Transplant. 2020 Apr;39(4):379-388
pubmed: 32033844
Transpl Infect Dis. 2021 Dec;23(6):e13739
pubmed: 34605596
BMJ. 2021 Mar 10;372:n436
pubmed: 33692022
Am J Transplant. 2017 May;17(5):1294-1303
pubmed: 27676455
Am J Transplant. 2012 Feb;12(2):477-84
pubmed: 22152000
JAMA. 2021 Jun 1;325(21):2204-2206
pubmed: 33950155